31,021 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Nomura Holdings Inc.

Key Points

• Nomura Holdings Inc. has acquired a new position in BioNTech SE by purchasing 31,021 shares valued at approximately $2.825 million according to a recent SEC filing.
• Several hedge funds increased their holdings in BioNTech, with BNP Paribas Financial Markets growing its position by 94.6% to own over $108 million worth of shares.
• Analysts remain optimistic, with BioNTech holding an average rating of "Moderate Buy" and an average target price of $135.80, with several firms lifting their price targets.

Nomura Holdings Inc. purchased a new position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 31,021 shares of the company's stock, valued at approximately $2,825,000.

A number of other hedge funds also recently modified their holdings of the stock. DAFNA Capital Management LLC increased its position in shares of BioNTech by 23.5% in the first quarter. DAFNA Capital Management LLC now owns 10,500 shares of the company's stock worth $956,000 after purchasing an additional 2,000 shares during the period. BNP Paribas Financial Markets increased its position in shares of BioNTech by 94.6% in the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company's stock worth $108,859,000 after purchasing an additional 581,173 shares during the period. B. Metzler seel. Sohn & Co. AG increased its position in shares of BioNTech by 34.3% in the first quarter. B. Metzler seel. Sohn & Co. AG now owns 16,066 shares of the company's stock worth $1,463,000 after purchasing an additional 4,107 shares during the period. Jump Financial LLC bought a new position in BioNTech in the first quarter valued at about $1,984,000. Finally, APG Asset Management N.V. grew its position in BioNTech by 5.8% in the first quarter. APG Asset Management N.V. now owns 49,600 shares of the company's stock valued at $4,181,000 after acquiring an additional 2,700 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Morgan Stanley lifted their target price on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Wells Fargo & Company set a $150.00 target price on BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. The Goldman Sachs Group assumed coverage on BioNTech in a research report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 target price on the stock. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Finally, Bank of America lifted their target price on BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $135.80.

BioNTech Stock Performance

NASDAQ:BNTX opened at $100.62 on Wednesday. The stock has a market cap of $24.19 billion, a P/E ratio of -62.89 and a beta of 1.39. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The stock's 50-day moving average is $109.51 and its 200-day moving average is $104.74. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The firm had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business's revenue for the quarter was up 102.6% on a year-over-year basis. During the same quarter last year, the firm posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. Equities research analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.